Ghent University Academic Bibliography

Advanced

A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)

Rabab M Gaafar, VEERLE SURMONT UGent, Giorgio V Scagliotti, Rob J Van Klaveren, Demetris Papamichael, John J Welch, Baktiar Hasan, Valter Torri and Jan Van Meerbeeck UGent (2011) EUROPEAN JOURNAL OF CANCER. 47(15). p.2331-2340
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
SUPPORTIVE CARE, CELL LUNG-CANCER, TRIAL, CARBOPLATIN, DOCETAXEL, ERLOTINIB, GEMCITABINE, COMBINATION, PACLITAXEL, PLUS, EORTC, EGFR, Gefitinib, Chemotherapy, Non-small cell lung cancer
journal title
EUROPEAN JOURNAL OF CANCER
Eur. J. Cancer
volume
47
issue
15
pages
2331 - 2340
Web of Science type
Article
Web of Science id
000296393700011
JCR category
ONCOLOGY
JCR impact factor
5.536 (2011)
JCR rank
25/190 (2011)
JCR quartile
1 (2011)
ISSN
0959-8049
DOI
10.1016/j.ejca.2011.06.045
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
2044481
handle
http://hdl.handle.net/1854/LU-2044481
date created
2012-02-24 15:29:53
date last changed
2012-02-28 09:50:24
@article{2044481,
  author       = {Gaafar, Rabab M and SURMONT, VEERLE and Scagliotti, Giorgio V and Van Klaveren, Rob J and Papamichael, Demetris and Welch, John J and Hasan, Baktiar and Torri, Valter and Van Meerbeeck, Jan},
  issn         = {0959-8049},
  journal      = {EUROPEAN JOURNAL OF CANCER},
  keyword      = {SUPPORTIVE CARE,CELL LUNG-CANCER,TRIAL,CARBOPLATIN,DOCETAXEL,ERLOTINIB,GEMCITABINE,COMBINATION,PACLITAXEL,PLUS,EORTC,EGFR,Gefitinib,Chemotherapy,Non-small cell lung cancer},
  language     = {eng},
  number       = {15},
  pages        = {2331--2340},
  title        = {A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)},
  url          = {http://dx.doi.org/10.1016/j.ejca.2011.06.045},
  volume       = {47},
  year         = {2011},
}

Chicago
Gaafar, Rabab M, VEERLE SURMONT, Giorgio V Scagliotti, Rob J Van Klaveren, Demetris Papamichael, John J Welch, Baktiar Hasan, Valter Torri, and Jan Van Meerbeeck. 2011. “A Double-blind, Randomised, Placebo-controlled Phase III Intergroup Study of Gefitinib in Patients with Advanced NSCLC, Non-progressing After First Line Platinum-based Chemotherapy (EORTC 08021/ILCP 01/03).” European Journal of Cancer 47 (15): 2331–2340.
APA
Gaafar, R. M., SURMONT, V., Scagliotti, G. V., Van Klaveren, R. J., Papamichael, D., Welch, J. J., Hasan, B., et al. (2011). A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). EUROPEAN JOURNAL OF CANCER, 47(15), 2331–2340.
Vancouver
1.
Gaafar RM, SURMONT V, Scagliotti GV, Van Klaveren RJ, Papamichael D, Welch JJ, et al. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). EUROPEAN JOURNAL OF CANCER. 2011;47(15):2331–40.
MLA
Gaafar, Rabab M, VEERLE SURMONT, Giorgio V Scagliotti, et al. “A Double-blind, Randomised, Placebo-controlled Phase III Intergroup Study of Gefitinib in Patients with Advanced NSCLC, Non-progressing After First Line Platinum-based Chemotherapy (EORTC 08021/ILCP 01/03).” EUROPEAN JOURNAL OF CANCER 47.15 (2011): 2331–2340. Print.